$INTI
Inhibitor Therapeutics, Inc.

2015 Q4 Form 10-Q Financial Statement

#000119312515365266 Filed on November 04, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $570.0K $600.0K $570.0K
YoY Change -3.39% 5.26% 137.5%
% of Gross Profit
Research & Development $470.0K $601.7K $167.0K
YoY Change 51.61% 260.36% -84.1%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.030M $1.202M $738.1K
YoY Change 14.44% 62.86% -42.89%
Operating Profit -$1.202M -$738.1K
YoY Change 62.86% -42.89%
Interest Expense $0.00 $0.00 $1.979K
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.030M -$1.200M -$740.0K
YoY Change 14.44% 62.16% -42.64%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.030M -$1.202M -$740.1K
YoY Change 14.44% 62.43% -42.74%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 245.4M shares 245.4M shares 41.42M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $600.0K $1.240M $380.0K
YoY Change 62.16% 226.32%
Cash & Equivalents $601.4K $1.243M $375.9K
Short-Term Investments
Other Short-Term Assets $34.41K $60.00K $47.24K
YoY Change -64.82% 27.01%
Inventory
Prepaid Expenses $34.41K
Receivables
Other Receivables
Total Short-Term Assets $635.9K $1.300M $423.1K
YoY Change 37.34% 207.22% 377672.32%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $250.0K $250.0K
YoY Change
Total Long-Term Assets $250.0K $250.0K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $635.9K $1.300M $423.1K
Total Long-Term Assets $250.0K $250.0K $0.00
Total Assets $885.9K $1.550M $423.1K
YoY Change 91.34% 266.31% 377672.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $383.4K $442.1K $331.0K
YoY Change 17.97% 33.58% 41.88%
Accrued Expenses $10.00K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $40.00K
YoY Change -100.0% -42.86%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $461.9K $540.4K $432.6K
YoY Change 15.21% 24.91% -21.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $461.9K $540.4K $432.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $461.9K $540.4K $430.0K
YoY Change 15.21% 25.68% -21.93%
SHAREHOLDERS EQUITY
Retained Earnings -$36.17M -$35.14M -$31.32M
YoY Change 12.26% 12.18% 11.74%
Common Stock $36.60M $36.15M $21.14K
YoY Change 13.35% 170881.09% 1019.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $424.0K $1.009M -$9.541K
YoY Change
Total Liabilities & Shareholders Equity $885.9K $1.550M $423.1K
YoY Change 91.34% 266.31% 377672.32%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$1.030M -$1.202M -$740.1K
YoY Change 14.44% 62.43% -42.74%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$640.0K -$650.0K -$380.0K
YoY Change 23.08% 71.05% 216.67%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 490.0K
YoY Change -100.0% -100.0% 276.92%
NET CHANGE
Cash From Operating Activities -640.0K -650.0K -380.0K
Cash From Investing Activities
Cash From Financing Activities 0.000 0.000 490.0K
Net Change In Cash -640.0K -650.0K 110.0K
YoY Change 6300.0% -690.91% 1000.0%
FREE CASH FLOW
Cash From Operating Activities -$640.0K -$650.0K -$380.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
375865
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
245353270 shares
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
245353270 shares
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
245353270 shares
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36124286
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
1009477
CY2015Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
98318
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
442088
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35139344
CY2015Q3 us-gaap Liabilities
Liabilities
540406
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1549883
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
24535
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
540406
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2015Q3 us-gaap Assets
Assets
1549883
CY2015Q3 us-gaap Assets Current
AssetsCurrent
1299883
CY2015Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
700000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
56611
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1243272
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
217
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
211419937 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
211419937 shares
CY2014Q4 us-gaap Liabilities
Liabilities
400899
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462978
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
32263890
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
62079
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
75933
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
324966
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32222953
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
21142
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
400899
CY2014Q4 us-gaap Assets
Assets
462978
CY2014Q4 us-gaap Assets Current
AssetsCurrent
462978
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
97817
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
365161
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-784740
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56949513 shares
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
63250
us-gaap Net Income Loss
NetIncomeLoss
-3077215
us-gaap Revenues
Revenues
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
37240
us-gaap Operating Income Loss
OperatingIncomeLoss
-3040684
us-gaap Share Based Compensation
ShareBasedCompensation
333882
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
375648
us-gaap Operating Expenses
OperatingExpenses
3040684
us-gaap Interest Expense
InterestExpense
36531
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1160388
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2122770
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
950000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
917914
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
61307
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
273638
hppi In Process Research And Development Paid In Stock And Warrants
InProcessResearchAndDevelopmentPaidInStockAndWarrants
1909860
hppi Noncash Interest Expense
NoncashInterestExpense
24666
hppi Issuance Of Common Stock For Common Stock Subscription Receivable
IssuanceOfCommonStockForCommonStockSubscriptionReceivable
1250000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1621889
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
dei Trading Symbol
TradingSymbol
HPPI
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
228324455 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P35M
us-gaap Net Income Loss
NetIncomeLoss
-2916391
us-gaap Revenues
Revenues
0
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2500000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
208794
us-gaap Operating Income Loss
OperatingIncomeLoss
-2916391
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
90000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
1273789
us-gaap Share Based Compensation
ShareBasedCompensation
1273789
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
878111
us-gaap Operating Expenses
OperatingExpenses
2916391
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2500000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1214969
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2500000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1701422
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
229507
hppi Issuance Of Common Stock In Payment Of Trade Payable
IssuanceOfCommonStockInPaymentOfTradePayable
90000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130115236 shares
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-740069
CY2014Q3 us-gaap Revenues
Revenues
0
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-738090
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
738090
CY2014Q3 us-gaap Interest Expense
InterestExpense
1979
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
166963
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
571127
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
601664
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
600397
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
245353270 shares
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-1202061
CY2015Q3 us-gaap Revenues
Revenues
0
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1202061
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
1202061

Files In Submission

Name View Source Status
0001193125-15-365266-index-headers.html Edgar Link pending
0001193125-15-365266-index.html Edgar Link pending
0001193125-15-365266.txt Edgar Link pending
0001193125-15-365266-xbrl.zip Edgar Link pending
d18401d10q.htm Edgar Link pending
d18401dex311.htm Edgar Link pending
d18401dex312.htm Edgar Link pending
d18401dex321.htm Edgar Link pending
d18401dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20150930.xml Edgar Link completed
hppi-20150930.xsd Edgar Link pending
hppi-20150930_cal.xml Edgar Link unprocessable
hppi-20150930_def.xml Edgar Link unprocessable
hppi-20150930_lab.xml Edgar Link unprocessable
hppi-20150930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending